[Glycogenosis type I. Therapy (author's transl)]

Area of Science:

• Biochemistry
• Pediatrics
• Metabolic Disorders

Background:

• Glucogenosis type I (GSD I) is a rare inherited metabolic disorder.
• It is characterized by impaired glucose production, leading to severe hypoglycemia and metabolic complications.
• Management strategies aim to correct metabolic derangements and improve patient outcomes.

Observation:

• Two new patients with GSD I were managed using a specialized diet.
• Various therapeutic interventions including diet, pharmacotherapy, and surgical options were reviewed.
• Treatment outcomes were assessed for metabolic acidosis, hypoglycemia, growth rate, hyperlipidemia, and uric acid levels.

Findings:

• Dietary management and other interventions led to significant improvement in metabolic acidosis and hypoglycemia.
• However, patient growth rate and hyperlipidemia levels did not show improvement.
• Administration of allopurinol effectively normalized elevated uric acid levels in the patients.

Implications:

• These findings highlight the complex management of GSD I, with variable responses to different therapies.
• The study suggests that while some metabolic parameters can be controlled, others like growth and lipid profiles may require further therapeutic strategies.
• The normalization of uric acid with allopurinol indicates a potential role for this drug in managing hyperuricemia associated with GSD I.